Recent research focusing on Tirzepatide at a dosage of 30mg is shedding new light on its potential benefits. Early findings suggest that this higher dosage may boost the drug's ability to control blood glucose, potentially offering more significant outcomes for individuals with insulin resistance. Further investigation is underway to fully evaluate